<DOC>
	<DOC>NCT00957203</DOC>
	<brief_summary>Patients with Parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study. The purpose of this study is to evaluate the safety and efficacy of KW-6002 administered long-term in patients with advanced Parkinson's disease treated with levodopa.</brief_summary>
	<brief_title>Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>1. Be willing and able to give written informed consent 2. Completion of the study 6002009 1. Minimental status examination score of 23 or less 2. Less than 70% of compliance in the study 6002009 3. Emergency deviation in the study 6002009 4. Pregnant females</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>end of dose wearing off</keyword>
	<keyword>OFF time</keyword>
</DOC>